Mediwound (MDWD) has released an update.
MediWound Ltd. reported a strong 2023 with $19 million in revenue and significant advancements for its enzymatic therapeutics, including the U.S., Japan, and India launch of NexoBrid® and anticipation for its potential blockbuster EscharEx® to enter Phase III trials in late 2024. The company boasts a $42 million cash runway extending into profitability and has seen robust demand, highlighted by NexoBrid’s critical role in treating burn casualties during conflict in Israel. Additionally, the company is expanding manufacturing capabilities to meet NexoBrid’s increasing demand and has secured considerable R&D funding from the U.S. Department of Defense and BARDA.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
